ArticlePLoS pathogens2014
A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.
Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.Antimicrobial agents and chemotherapy · 2020Trial
- The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2015Trial
- Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.Journal of virology · 2025Article
- CD4+ but not CD8+ T cells are required for protection against severe guinea pig cytomegalovirus infections.PLoS pathogens · 2024Article
- Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.The Journal of clinical investigation · 2022Article
- Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.Viruses · 2022Article
- The Placental Response to Guinea Pig Cytomegalovirus Depends Upon the Timing of Maternal Infection.Frontiers in immunology · 2021Article
- Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Cytomegalovirus infection elicits a conserved chemokine response from human and guinea pig amnion cells.Virology · 2020Article
- Review
- Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.Journal of virology · 2020Article
- Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.The Journal of infectious diseases · 2020Review
- Article
- Development of novel vaccines against human cytomegalovirus.Human vaccines & immunotherapeutics · 2019Review
- Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.Journal of virology · 2018Article
- A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.Expert review of vaccines · 2018Review
- Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection.Viruses · 2018Review
- Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.Journal of virology · 2018Review
- A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection.NPJ vaccines · 2018Review
- Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Clinical and vaccine immunology : CVI · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) is the most common cause of congenital virus infection. Congenital HCMV infection occurs in 0.2-1% of all births, and causes birth defects and developmental abnormalities, including sensorineural hearing loss and developmental delay. Several key studies have established the guinea pig as a tractable model for the study of congenital HCMV infection and have shown that polyclonal antibodies can be protective. In this study, we demonstrate that an anti-guinea pig CMV (GPCMV) glycoprotein H/glycoprotein L neutralizing monoclonal antibody protects against fetal infection and loss in the guinea pig. Furthermore, we have delineated the kinetics of GPCMV congenital infection, from maternal infection (salivary glands, seroconversion, placenta) to fetal infection (fetus and amniotic fluid). Our studies support the hypothesis that a neutralizing monoclonal antibody targeting an envelope GPCMV glycoprotein can protect the fetus from infection and may shed light on the therapeutic intervention of HCMV congenital infection in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.